$HYPR

Hyperfine, Inc.

Hyperfine develops and sells the Swoop® Portable MR Imaging® System, an AI-powered, portable, ultra-low-field brain MRI device for healthcare professionals. Designed for use at the bedside and in hospitals, emergency departments, clinics and neurology offices, the system produces images of the head that trained physicians can use to inform diagnosis and care. Its Optive AI™ software processes images, and the company offers imaging sequences including T1, T2, diffusion-weighted imaging and FLAIR. Hyperfine also offers PULSE, a subscription-based platform providing Swoop® system users with research sequences, community-developed sequences and raw imaging data. Hyperfine sells the Swoop® system, typically with an annual software, service and support agreement that begins after a one-year warranty; agreements are initially sold in 36- or 60-month terms. It sells directly in the United States and uses distributors in Canada and select international markets. Its wholly owned subsidiary Liminal has a suspended program to develop a device for non-invasively measuring brain vital signs. Hyperfine is headquartered in Guilford, Connecticut.

0
2
1

No SEC Form 4 filings for $HYPR in the last 30 days.

See all $HYPR insider activity →
Med

B.Riley lowers Hyperfine stock price target on valuation adjustment

B.Riley lowered its price target on Hyperfine Inc. (HYPR) to $1.40 from $1.60, maintaining a Buy rating. Q3 2026 revenue was $6.0M, beating estimates, with a loss per share of $0.06. Revenue grew 73% YoY, and gross margin expanded to 57%. The company reaffirmed fiscal 2026 guidance and extended its cash runway into 2028.

What Hyperfine (HYPR) Said on Its Q3 Earnings Call

Hyperfine (HYPR) reported $13.8M revenue for the first nine months, up 66% YoY, with 36 systems sold. Management maintained its revenue forecast, citing capital equipment deal sizes and visibility. The company discussed its 'land-and-expand' strategy in health systems and progress in contrast imaging studies. Hyperfine also expanded internationally and explored new markets like memory clinics and wellness.

HYPR sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning HYPR (Hyperfine, Inc.). Coverage has skewed bearish: 0 bullish, 2 neutral, and 1 bearish.

Recent HYPR coverage spans earnings, financial news and regulation.

What's driving HYPR

AlphAI scores every news story that mentions HYPR with an AI model for sentiment and relevance, and aggregates insider trades from Hyperfine, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $HYPR

Score

What Hyperfine (HYPR) Said on Its Q3 Earnings Call

Hyperfine (HYPR) reported $13.8M revenue for the first nine months, up 66% YoY, with 36 systems sold. Management maintained its revenue forecast, citing capital equipment deal sizes and visibility. The company discussed its 'land-and-expand' strategy in health systems and progress in contrast imaging studies. Hyperfine also expanded internationally and explored new markets like memory clinics and wellness.

$HYPRMedEarnings

Hyperfine, Inc. Reports Third Quarter 2026 Financial Results

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine, Inc. Reports Third Quarter 2026 Financial Results GUILFORD, Conn.--(BUSINESS WIRE)--November 9, 2026--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portab

Lucid Capital Markets initiates Hyperfine stock with buy rating

Lucid Capital Markets initiated coverage on Hyperfine Inc. (NASDAQ:HYPR) with a buy rating and $2.00 price target, citing its innovative Swoop MRI system and growth potential. The stock trades near its 52-week low at $0.72. Hyperfine reported Q2 2026 revenue of $3.9M, up 45% YoY but below estimates, with adjusted losses meeting expectations. The company has over 200 systems deployed globally and recently received FDA clearance for its Optive AI software update.

Six German symphony performances bring brain scans onstage

Hyperfine (HYPR) received CE and UKCA approvals for its Optive AI software, enhancing the Swoop system's imaging capabilities. The company is supporting 'Notes and Neurons,' a German initiative combining music and brain health research using the Swoop system for live brain imaging. Hyperfine aims to expand the Swoop system's use in brain health applications, with ongoing rollout in four international markets.

$HYPRMedEarnings

Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to…

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million Preliminary Revenue Represents 53% Sequential Quarterly Growth; Company Reaffirms 2026 Financial Gu

Related tickers